Clinical trial
Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced…
NCT00322348 · AstraZeneca, Industry · Completed
Key facts
| NCT number | NCT00322348 |
|---|---|
| Title | Study of Zoladex Given Every 12 Weeks Versus Given Every Month in Advanced Breast Cancer (ABC) Pre-menopausal Women |
| Official title | An Open-label, Randomised, Parallel Group, Multicentre Study to Compare ZOLADEX 10.8 mg Given Every 12 Weeks With ZOLADEX 3.6 mg Given Every 4 Weeks in Pre-menopausal Women With Oestrogen Receptor Positive Advanced Breast Cancer |
| Lead sponsor | AstraZeneca, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Advanced Breast Cancer |
| Intervention type | Drug |
| Interventions | Goserelin acetate |
| Enrollment | 98 |
| Start date | Apr 1, 2006 |
| Completion | Nov 1, 2009 |
| First posted | May 5, 2006 |
| Last update posted | Jan 24, 2011 |
| Countries | Czechia, Russia, Ukraine |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: